ArticleCureus2025
Hormonal Changes During Menopause and Their Impact on Bone Health: Insights from Orthopedic and Reproductive Medicine.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Adiposity Excess and Vertebral Fractures in Patients With Breast Cancer Taking Aromatase Inhibitors.JAMA network open · 2026Article
- Mechanistic Insights Into the Estrogen-Like Effects of Selenium-Enriched Armillaria on Anti-Osteoporosis in Ovariectomized Rats.Biological trace element research · 2026Article
- Article
- Hyperoside promotes osteoblast differentiation by increasing osteoclast-derived migrasomes to alleviate osteoporosis.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Menopause is characterized by profound hormonal alterations, including a decline in estradiol and progesterone with compensatory rises in follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These changes have been implicated in the pathogenesis of bone loss and osteoporosis, yet their precise contribution in the South Asian population remains underexplored. This study aimed to investigate the relationship between hormonal changes during menopause and their impact on bone health, with integrated perspectives from orthopedic and reproductive medicine. Methods A retrospective study was conducted at the University of Lahore, Lahore, Pakistan, utilizing medical records of postmenopausal women aged 45-65 years over a 12-month period. A total of 180 participants with complete hormonal and bone health data were included through purposive sampling. Data collected included demographic characteristics, menopausal duration, lifestyle factors, serum hormone levels (estradiol, progesterone, FSH, LH), biochemical markers (serum calcium, vitamin D, alkaline phosphatase), and bone mineral density (BMD) assessed via dual-energy X-ray absorptiometry (DEXA). Statistical analyses included t-tests, chi-square tests, Pearson's correlation, and multivariate linear regression, with p < 0.05 considered significant. Results Women with menopause ≥5 years exhibited significantly lower estradiol (21.4 ± 8.6 pg/mL vs. 36.8 ± 12.4 pg/mL, p < 0.001) and higher FSH (68.7 ± 12.5 mIU/mL vs. 51.6 ± 9.4 mIU/mL, p < 0.001). Lumbar spine BMD was markedly reduced in this group (0.81 ± 0.13 g/cm² vs. 0.94 ± 0.11 g/cm², p < 0.001), with higher rates of osteopenia (49.1%) and osteoporosis (25.5%). Biochemical markers showed lower calcium and vitamin D, alongside elevated alkaline phosphatase. Correlation analysis demonstrated a positive association between estradiol and BMD (r = 0.46, p < 0.001) and a negative association with FSH (r = -0.39, p < 0.001). Multivariate regression identified estradiol as the strongest positive predictor and FSH as the strongest negative predictor of BMD, independent of age, BMI, and lifestyle factors. Conclusion Hormonal shifts during menopause, particularly reduced estradiol and elevated FSH, exert a dominant influence on bone health deterioration, surpassing the effects of age, BMI, and lifestyle. Early identification and targeted interventions addressing endocrine changes may be crucial for mitigating osteoporosis risk in postmenopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.